Powered by
EPIPEN SALES TAKE MAJOR HIT : SKYROCKETING COST,  MORE COMPETITION CITED IN ANALYSIS 
Mar 7, 2017 - Pittsburgh Post-Gazette

Concerns over the soaring cost of Mylan's EpiPen, plus increased competition, appear to have taken a toll on sales of the brand-name allergy shot.

Prescriptions for EpiPen alternatives surged to 28.9 percent of the market in February, up from 5.3 percent in December, according to a report by medical records and billing company Athenahealth in Watertown, Mass.

Put another way, the brand-name product's market share has fallen from around 95 percent to around 71 percent in February, the

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox